Search clinical trials for: Dopamine Antagonists

Total 35341 results

Nathalie Charpak
Hospital Universitario San Ignacio; Pontificia Universidad Javeriana

Completed

Methoclopramide for Gastroesophageal Reflux in Premature Infants

Gastroesophageal Reflux

Colombia
Assiut University
Esam Hamed; Wafaa Hamza

Unknown

Ultrasound Assessment of Metoclopramide Effect on Gastric Volume in Cesarean Section

Aspiration Pneumonia

Egypt
Millennium Pharmaceuticals, Inc.

Terminated

TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)

Critical Illness | Enteral Nutrition | Enteral Feeding Intolerance

United States, Canada, Australia, United Kingdom
National University Hospital, Singapore
The University of Western Australia

Completed

Maxolon to Improve Breastmilk Supply in Diabetic Women: a Randomised Controlled Trial (Maxalon)

Breastfeeding

Singapore
Pamukkale University

Completed

Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide

Nausea | Akathisia
National University Hospital, Singapore

Completed

Metoclopramide to Aid Establishment of Breastfeeding:a Randomised Controlled Trial

Breastfeeding

Singapore
Janssen-Cilag International NV

Completed

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics (PROSIPAL)

Schizophrenia

France, Ukraine, United Kingdom, Germany, Taiwan, Spain, Poland, Bulgaria, Romania, Russian Federation, South Africa, Greece, Israel, Korea, Republic of, Belgium, Estonia, Turkey, Czech Republic, Austria, Hungary, Lithuania, Slovakia and more
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

Poland, United States, Belgium, Taiwan, Spain, Malaysia, Korea, Republic of, Thailand, Slovakia, Croatia
Janssen Korea, Ltd., Korea

Completed

PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia (PANDORA)

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone

Schizophrenia
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Schizophrenia (Recent-onset)

United States
Janssen-Cilag Ltd.

Completed

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Schizophrenia

France, Germany, Spain, Israel, Malaysia, Turkey, Taiwan, Greece, Korea, Republic of, Russian Federation, Netherlands, United Kingdom, Croatia, Denmark, Saudi Arabia
University of Miami
Ortho-McNeil, Inc.

Withdrawn

Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism

Bipolar Disorder
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder

United States
Janssen-Cilag G.m.b.H

Terminated

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Schizophrenia

Germany
Luye Pharma Group Ltd.
Alliance for Clinical Trials in Oncology; Evolution Research Group

Completed

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Schizophrenia Patients

United States
Janssen-Cilag International NV

Completed

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Schizophrenia

Germany, Spain, Belgium, Hungary, France, Italy, United Kingdom
Janssen Cilag N.V./S.A.

Completed

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Psychomotor Agitation | Acute Disease

Belgium
Seoul National University Hospital

Completed

The Effect of Paliperidone Palmitate in Schizophrenia (sustenna)

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Schizophrenia
NeuroRx, Inc.
Target Health Inc.

Completed

NRX101 Glx Biomarker Validation Study (NRX-GLX)

Suicidal Ideation | Bipolar Depression

United States
Sunovion

Completed

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. (PEARL 3)

Schizophrenia

United States, Russian Federation, India, Romania, Ukraine
Sunovion

Completed

Pediatric Open-Label Extension Study

Schizophrenia | Bipolar Depression | Autism

Korea, Republic of, United States, Malaysia, Bulgaria, Poland, Mexico, Colombia, France, Hungary, Philippines, Puerto Rico, Romania, Russian Federation, Spain, Ukraine
Sunovion

Completed

Pediatric Schizophrenia Efficacy and Safety Study

Schizophrenia

France, United States, Korea, Republic of, Poland, Spain, Puerto Rico, Colombia, Hungary, Bulgaria, Mexico, Malaysia, Philippines, Romania, Russian Federation, Ukraine, Belgium, United Kingdom
University of California, Irvine
Dainippon Sumitomo Pharma America

Completed

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Schizophrenia | Major Depressive Disorder | Mental Disorder | Bipolar I Disorder

United States
VA Office of Research and Development

Withdrawn

VA Aripiprazole vs Esketamine for Treatment Resistant Depression (VAST-D II)

Depressive Disorder, Major

United States
Vanguard Research Group
Otsuka America Pharmaceutical

Completed

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics (PRELAPSE)

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Schizophrenia | Major Depressive Disorder | Bipolar 1 Disorder

United States
Seoul National University Hospital
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

Major Depressive Disorder

Korea, Republic of
Wei Hao

Terminated

A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Methamphetamine Dependence

China
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
National Taiwan University Hospital
Yu-Li Hospital; Yu-Li Veterans Hospital

Completed

Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome

Metabolic Syndrome X

Taiwan
University of Miami
Alkermes, Inc.

Recruiting

C-Cog in Early Course Schizophrenia Study

Schizophrenia

United States
Otsuka Beijing Research Institute

Completed

Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

China
University of California, Los Angeles

Completed

Combination Treatment for Augmenting Language in Children With ASD (PIII)

Autism Spectrum Disorder

United States
University of Maryland, Baltimore

Terminated

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder (PAMS)

Bipolar Disorder

United States
Northwestern University
National Alliance for Research on Schizophrenia and Depression; Pfizer

Completed

Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

Schizophrenia | Schizoaffective Disorder | Bipolar Disorder

United States
Fundación Marques de Valdecilla
Centro de Investigación Biomédica en Red de Salud Mental; Instituto de Investigación...

Completed

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up (PAFIP2_3Y)

Psychotic Disorders | Schizophrenia

Spain
Fundación Marques de Valdecilla
Centro de Investigación Biomédica en Red de Salud Mental; Instituto de Investigación...

Completed

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up (PAFIP2_nc1Y)

Psychotic Disorders | Schizophrenia

Spain
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (ARRIVE- EU)

Schizophrenia

Belgium, Bulgaria, Canada
Janssen-Cilag International NV

Completed

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia

France, Poland, Germany, Spain, Slovenia, Bulgaria, Romania, Israel, Greece, Sweden, Turkey, Czech Republic, Hungary, Lithuania, Latvia, Portugal, Croatia, Slovakia, Austria, United Kingdom, Estonia, Ireland, Denmark, Saudi Arabia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole in Adolescents With Schizophrenia (APEX 239)

Schizophrenia

United States, Puerto Rico
Sunovion

Completed

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia (PEARL 3 Ext)

Chronic Schizophrenia

United States, Colombia, India, Ukraine, Russian Federation, Romania
Sunovion

Completed

Safety and Tolerability Study of Drug to Treat Schizophrenia

Schizophrenia

United States
The University of Hong Kong

Recruiting

Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia (MainRexult)

Anxiety Depression | Schizophrenia and Related Disorders

Hong Kong
The University of Hong Kong
North District Hospital; Queen Mary Hospital, Hong Kong

Recruiting

Substance Misuse To Psychosis for Stimulants

Schizophrenia and Related Disorders | Stimulant Dependence | Pharmacotherapy | Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis) | Stimulant Abuse

Hong Kong
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics (MAESTRO)

Schizophrenia | Antipsychotics | Long-Acting Injection | LAI | Aripiprazole

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States

Search clinical trials for: Dopamine Antagonists

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations